Laurus Investment Counsel’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.4M | Sell |
71,685
-10,680
| -13% | -$1.98M | 12.11% | 2 |
|
|
2025
Q4 | $16.4M | Sell |
82,365
-4,155
| -5% | -$754K | 13.38% | 1 |
|
|
2025
Q3 | $13.5M | Hold |
86,520
| – | – | 9.26% | 2 |
|
|
2025
Q2 | $13.1M | Sell |
86,520
-3,660
| -4% | -$488K | 8.57% | 4 |
|
|
2025
Q1 | $13.6M | Buy |
90,180
+11,030
| +14% | +$1.85M | 9.06% | 3 |
|
|
2024
Q4 | $14.6M | Buy |
79,150
+7,435
| +10% | +$1.43M | 7.52% | 5 |
|
|
2024
Q3 | $19.1M | Hold |
71,715
| – | – | 7.39% | 4 |
|
|
2024
Q2 | $20.3M | Hold |
71,715
| – | – | 8.38% | 3 |
|
|
2024
Q1 | $26.3M | Hold |
71,715
| – | – | 9.23% | 1 |
|
|
2023
Q4 | $22.5M | Buy |
71,715
+100
| +0.1% | +$19.7K | 8.14% | 3 |
|
|
2023
Q3 | $18.9M | Buy |
71,615
+1,207
| +2% | +$248K | 7.95% | 2 |
|
|
2023
Q2 | $19.6M | Sell |
70,408
-150
| -0.2% | -$29.8K | 7.04% | 4 |
|
|
2023
Q1 | $19.3M | Buy |
70,558
+555
| +0.8% | +$126K | 6.88% | 4 |
|
|
2022
Q4 | $20.7M | Sell |
70,003
-627
| -0.9% | -$137K | 7.68% | 1 |
|
|
2022
Q3 | $19M | Buy |
70,630
+4,145
| +6% | +$895K | 6.95% | 3 |
|
|
2022
Q2 | $14.2M | Buy |
66,485
+14,985
| +29% | +$3.66M | 6.84% | 3 |
|
|
2022
Q1 | $14.6M | Buy |
51,500
+245
| +0.5% | +$75.5K | 5.52% | 8 |
|
|
2021
Q4 | $24.7M | Buy |
51,255
+340
| +0.7% | +$132K | 6.39% | 4 |
|
|
2021
Q3 | $26.7M | Sell |
50,915
-5,465
| -10% | -$2.27M | 7.59% | 2 |
|
|
2021
Q2 | $25.9M | Sell |
56,380
-2,750
| -5% | -$918K | 7.95% | 2 |
|
|
2021
Q1 | $17.1M | Sell |
59,130
-13,470
| -19% | -$3.74M | 6.6% | 2 |
|
|
2020
Q4 | $18.1M | Sell |
72,600
-15
| -0% | -$3.57K | 7.05% | 2 |
|
|
2020
Q3 | $16.4M | Buy |
72,615
+220
| +0.3% | +$45.7K | 8.08% | 1 |
|
|
2020
Q2 | $12.6M | Buy |
72,395
+65
| +0.1% | +$10.4K | 6.76% | 6 |
|
|
2020
Q1 | $9.13M | Buy |
72,330
+7,355
| +11% | +$1.1M | 6.59% | 6 |
|
|
2019
Q4 | $9.93M | Buy |
64,975
+51,020
| +366% | +$7.06M | 5.61% | 11 |
|
|
2019
Q3 | $1.85M | Buy |
13,955
+7,990
| +134% | +$1.07M | 1.25% | 14 |
|
|
2019
Q2 | $846K | Hold |
5,965
| – | – | 0.6% | 19 |
|
|
2019
Q1 | $866K | Hold |
5,965
| – | – | 0.68% | 16 |
|
|
2018
Q4 | $675K | Hold |
5,965
| – | – | 0.63% | 18 |
|
|
2018
Q3 | $803K | Hold |
5,965
| – | – | 0.58% | 15 |
|
|
2018
Q2 | $670K | Buy |
5,965
+1,200
| +25% | +$130K | 0.48% | 18 |
|
|
2018
Q1 | $509K | Hold |
4,765
| – | – | 0.43% | 18 |
|
|
2017
Q4 | $522K | Buy |
+4,765
| New | +$519K | 0.42% | 19 |
|
Other funds holding CRL
Laurus Investment Counsel's CRL Position: Q1 2026 in Review
Laurus Investment Counsel reduced its Charles River Laboratories (CRL) stake by 13% in Q1 2026, selling an estimated $1.98M and leaving 71,685 shares worth $12.4M. The position accounts for 12.11% of the portfolio, ranked #2.
Laurus Investment Counsel first reported a position in CRL in Q4 2017 and has held it in 34 quarters since. The position peaked at $26.7M in Q3 2021. 560 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Laurus Investment Counsel held 71,685 shares of Charles River Laboratories worth $12.4M as of Q1 2026.
- Laurus Investment Counsel sold 10,680 Charles River Laboratories shares in Q1 2026, an estimated $1.98M.
- Charles River Laboratories made up 12.11% of Laurus Investment Counsel's portfolio in Q1 2026, its #2 holding.
- Laurus Investment Counsel first reported a position in Charles River Laboratories in Q4 2017 and has held it in 34 quarters since.
- Laurus Investment Counsel's Charles River Laboratories position peaked at $26.7M in Q3 2021.
- 560 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Laurus Investment Counsel's 13F filing for Q1 2026, filed 1 Apr 2026.